The Efficacy of Graminex® Flower Pollen Extracts in Healthy Women With Urinary Incontinence

Graminex LLC190 enrolled

Overview

The primary objective of this study is to investigate the effect of Graminex® Flower Pollen Extracts in healthy women with urinary incontinence. The change in severity of urinary incontinence between baseline and 24 weeks will be assessed by an International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and compared between the investigational product and placebo groups. Additionally, the safety and tolerability of Graminex® Flower Pollen Extracts, as compared to placebo, will be measured by the occurrence of and/or changes in treatment-emergent adverse events (AEs).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

190

Conditions

Urinary Incontinence

Interventions

PlaceboOTHER

One capsule of placebo will be taken twice daily for 24 weeks.

Water soluble pollen extract fractionDIETARY_SUPPLEMENT

Each capsule contains 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (360 mg/day) for 24 weeks.

Lipid soluble pollen extract fraction + water soluble pollen extract fractionDIETARY_SUPPLEMENT

Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction. One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.

Eligibility

Sex: FEMALEMin age: 40 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Females between the ages of 40-75 inclusive. 2. BMI 18.5 kg/m2 - 34.9 kg/m2 inclusive. 3. Involuntary loss of urine (incontinence) persisting for at least 1 month as determined by a score ≥ 5 on the ICIQ-SF questionnaire at the screening visit. 4. Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation) or have been post-menopausal (natural or surgically) for at least 1 year prior to screening. Or, Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening 5. Agree to keep lifestyle habits consistent (dietary habits and physical activity patterns) for the duration of the trial. 6. Willing to maintain current caffeine intake. Individuals with excessive habitual caffeine intake (\>3 cups coffee or \>4 cups caffeinated tea per day or \>2 energy drinks) will be required to reduce consumption for 2 weeks prior to baseline. 7. Healthy as determined by laboratory results, medical history, and physical exam. 8. Has given voluntary, written, informed consent to participate in the study. Exclusion Criteria: 1. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial. 2. Allergy or sensitivity to test product ingredients. 3. Treatment (ie. pessary) or surgery (ie. sling, mesh) for urinary incontinence from a continence specialist (ie. urologist, urogynecologist, gynecologist) within the past 5 years. 4. Treatment for overactive or neurogenic bladder in previous 3 months (ie. neuromodulation, botox). 5. Initiation of pelvic floor therapy in the previous 3 months. 6. Current utilization of a catheter for urination. 7. Current urinary tract infection (UTI, confirmed by laboratory analysis), verbal confirmation of infection in previous 3 months or history of recurrent UTIs. 8. Women who are currently taking medications for urinary incontinence/overactive bladder (see Section 6.3.1). 9. Irregular menstrual periods within the previous 6 months (less than 21 or greater than 33 days between cycles). 10. Women who are within 1-year postpartum. 11. Genital malformation (i.e. Vaginal fistula) or vaginal and/or vulvar disorder (i.e. vulvovaginal atrophy). 12. Women on hormone replacement therapy (oral or topical), unless on a stable dose for ≥6 months. 13. Metal implants that may affect the DXA scan results will be assessed on case-by-case basis by the QI. 14. Current, chronic constipation reviewed on a case-by-case basis by the QI. 15. Current or history of diabetes. 16. Current or history of bladder tumour. 17. Current sexually transmitted infection (confirmed by laboratory analysis), or verbal confirmation of infection in previous 3 months. 18. Current or history of liver, kidney or heart disease. 19. Current or pre-existing unstable thyroid condition. Treatment on a stable dose of medication for over one year will be reviewed on a case-by-case basis by the QI . 20. Current or history of bleeding disorders. 21. Clinically significant abnormal laboratory results at screening. 22. Excessive consumption of alcohol equivalent to \>2 alcoholic drinks/day (average). 23. Alcohol or drug abuse within the last 6 months. 24. Individuals who are cognitively impaired and/or who are unable to give informed consent. 25. Any autoimmune disease or immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C positive). 26. Participation in other clinical research trials one month prior to or during enrollment will be assessed case-by-case by the QI. 27. Any other condition, that, in the opinion of the QI, may adversely affect the participant's ability to provide written informed consent and complete the study or its measures, or pose significant risk to the participant.

Locations (1)

KGK Science Inc.

London, Ontario, Canada

Outcomes

Primary Outcomes

The change in severity of urinary incontinence between baseline and 24 weeks.

The change in severity of urinary incontinence between baseline and 24 weeks as assessed by the ICIQ-SF will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.

Time frame: baseline and 24 weeks

Secondary Outcomes

The change in severity of urinary incontinence between baseline and week 6, 12, and 18.

The change in severity of urinary incontinence between baseline and week 6, 12, and 18 as assessed by the ICIQ-SF will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.

Time frame: baseline, week 6, week 12, week 18

The change in frequency of urinary incontinence between baseline and week 6, 12, 18, and 24.

The change in frequency of urinary incontinence between baseline and week 6, 12, 18, and 24 as assessed by void diary will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.

Time frame: baseline, week 6, week 12, week 18, week 24

The change in daily urinary leakage volume between baseline and week 6, 12, 18, and 24.

The change in daily urinary leakage volume between baseline and week 6, 12, 18, and 24 as assessed by 24-hour pad weight will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.

Time frame: baseline, week 6, week 12, week 18, week 24

The change in stress-induced urinary leakage volume between baseline and week 24.

The change in stress-induced urinary leakage volume between baseline and week 24 as assessed by pad weight following a provocative maneuvers challenge will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.

Time frame: baseline, week 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.